Tarsus director receives 1,383 shares via RSU vest
Tarsus Pharmaceuticals, Inc. director David E. I. Pyott acquired common stock through equity compensation rather than open‑market trading.
Rhea-AI Filing Summary
Tarsus Pharmaceuticals, Inc. director David E. I. Pyott acquired common stock through equity compensation rather than open‑market trading. On April 24, 2026, 1,383 shares of common stock were issued upon settlement of vested Restricted Stock Units (RSUs), with each RSU converting into one share.
The RSUs vested in full on that date, subject to his continuous service. Following these transactions, he holds 1,383 shares directly and 7,991 shares indirectly through the David E.I. Pyott Trust.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 1,383 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,383 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Footnotes (3)
- F1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
- F2. Each RSU represents a contingent right to receive one share of the Company's common stock.
- F3. The RSUs vested in full on April 24, 2026, subject to the Reporting Person's continuous service.
Key Figures
Key Terms
Restricted Stock Units financial
derivative exercise/conversion financial
contingent right financial
indirect ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Tarsus (TARS) director David Pyott report in this Form 4?
What are Restricted Stock Units (RSUs) in the Tarsus (TARS) Form 4?
When did the Tarsus (TARS) RSUs reported by David Pyott vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.